UAE 2nd Country Worldwide To Approve Lung Cancer Drug 'Lumakras'
- Publish date: Sunday، 05 December 2021
- Related articles
- World Bank: Bahrain is the Second Most Improving Country in the GCC
- The Most Powerful Arabs in Bahrain 2023
- Six Arrested in Bahrain for Smuggling Narcotics in Potatoes
The UAE's Ministry of Health and Prevention (MoHAP) has recently approved the registration and use of Amgen’s lung cancer drug Lumakras, following the approval of the US Food and Drug Administration (FDA).
فيديو ذات صلة
This browser does not support the video element.
This will provide lung cancer patients early access to this innovative drug to help speed up their treatment plan and improve the quality of their life.
LUMAKRAS is supplied as a film-coated tablet for oral use containing 120mg of Sotorasib. The drug is prescribed to adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
The approval of this innovative treatment in the second country in the world comes a week after the UAE approved the emergency use of a highly effective new treatment for COVID-19, becoming the first country in the world to register the drug following the FDA approval.
Dr. Ahmed Mostafa, country manager of Amgen in GCC, said, "We are extremely proud of the UAE's approval for Lumakras drug, making it the second country in the world after the USA that approves and licences the medicine.
This article was previously published on UAE Moments.To see the original article, click here